Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2026 16:30 ET | Source: IN8bio, Inc

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 06, 2026 08:00 ET | Source: IN8bio, Inc

IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences

IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
April 03, 2026 16:00 ET | Source: IN8bio, Inc

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 12, 2026 16:01 ET | Source: IN8bio, Inc

IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results
February 24, 2026 08:00 ET | Source: IN8bio, Inc

IN8bio to Present at TD Cowen 46th Annual Health Care Conference

IN8bio to Present at TD Cowen 46th Annual Health Care Conference
February 09, 2026 08:00 ET | Source: IN8bio, Inc

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
February 03, 2026 08:00 ET | Source: IN8bio, Inc

IN8bio to Present at Upcoming Investor and Scientific Conferences in February

IN8bio to Present at Upcoming Investor and Scientific Conferences in February
January 12, 2026 08:00 ET | Source: IN8bio, Inc

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a...
December 19, 2025 08:00 ET | Source: IN8bio, Inc

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
November 06, 2025 16:00 ET | Source: IN8bio, Inc

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights